A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
- Conditions
- Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
- Registration Number
- EUCTR2008-006265-93-SE
- Lead Sponsor
- St Eriks Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
CRVO with a duration of 6 months or less. Visual acuity between 0.025-0.4 Snellen (5-67 ETDRS letters).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Previous CRVO treatment in study eye. Duration > 6 months. Previous treatment in study eye with anti-VEGF agents.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To study whether intravitreal bevacizumab (Avastin®) results in significant visual improvement in patients with CRVO as compared to the natural course of the disease. ;Secondary Objective: To study whether intravitreal bevacizumab (Avastin®) results in significantly decreased macular edema, reduced laser scatter treatments and decreased iris rubeosis in patients with CRVO as compared to the natural course of the disease. ;Primary end point(s): The proportion of patients gaining 15 ETDRS letters or more after 6 months.
- Secondary Outcome Measures
Name Time Method